Youtao Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Youtao Xu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Fanchen Meng
Department of Thoracic Surgery, Jiangsu Key Laboratory of Innovative Cancer Diagnosis & Therapeutics, Jiangsu Cancer Hospital & Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Institute of Cancer Research , Nanjing
13 shared publications - Jianyu Li
The Fourth Clinical College of Nanjing Medical University, Nanjing, PR China
13 shared publications - Jing Tan
Department of Anesthesiology, Jiangsu Cancer Hospital & Nanjing Medical University Affiliated Cancer Hospital & Jiangsu Institute of Cancer Research, Nanjing, PR China
13 shared publications - Qinglin Wang
Department of Thoracic Surgery, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China
13 shared publications - Qinhong Sun
The Fourth Clinical College of Nanjing Medical University, Nanjing, PR China
13 shared publications - Rong Yin
Department of Thoracic Surgery, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China
13 shared publications
Latest Publications
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Data from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer
Drug-tolerant persister (DTP) cells drive therapeutic resistance in EGFR-mutant lung adenocarcinoma. Using single-cell RNA sequencing, we identified a clinically significant RGS5+MYL9+ cancer-associated fibroblast (CAF) population that was associated with EGFR tyrosine kinase inhibitor (TKI) resistance and poor prognosis. These CAFs were recruited to DTP niches via CCL11 signaling, and they formed tunneling nanotubes through Miro1/RhoA activation induced by TKI-generated mitochondrial reactive oxygen species. Remarkably, RGS5+MYL9+ CAFs functioned as “metabolic sinks” by accepting tumor-derived damaged mitochondria, thereby promoting DTP survival. Treatment with fasudil, a Rho kinase inhibitor, effectively blocked mitochondrial transfer and restored sensitivity to the EGFR-TKI osimertinib in vivo. Together, this work reveals targetable stromal–tumor cross-talk that sustains DTP populations, proposing a combination therapy for overcoming EGFR-TKI resistance.Significance:Pharmacological blockade of nanotube-mediated mitochondrial transfer between tumor cells and RGS5+MYL9+ fibroblasts effectively overcome tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer, offering a clinically applicable strategy to enhance EGFR inhibitor efficacy.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer
Drug-tolerant persister (DTP) cells drive therapeutic resistance in EGFR-mutant lung adenocarcinoma. Using single-cell RNA sequencing, we identified a clinically significant RGS5+MYL9+ cancer-associated fibroblast (CAF) population that was associated with EGFR tyrosine kinase inhibitor (TKI) resistance and poor prognosis. These CAFs were recruited to DTP niches via CCL11 signaling, and they formed tunneling nanotubes through Miro1/RhoA activation induced by TKI-generated mitochondrial reactive oxygen species. Remarkably, RGS5+MYL9+ CAFs functioned as “metabolic sinks” by accepting tumor-derived damaged mitochondria, thereby promoting DTP survival. Treatment with fasudil, a Rho kinase inhibitor, effectively blocked mitochondrial transfer and restored sensitivity to the EGFR-TKI osimertinib in vivo. Together, this work reveals targetable stromal–tumor cross-talk that sustains DTP populations, proposing a combination therapy for overcoming EGFR-TKI resistance.Significance:Pharmacological blockade of nanotube-mediated mitochondrial transfer between tumor cells and RGS5+MYL9+ fibroblasts effectively overcome tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer, offering a clinically applicable strategy to enhance EGFR inhibitor efficacy.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer
Figure S7. RGS5+MYL9+ CAFs protect against EGFR-TKI-induced mitochondrial dysfunction in vitro. (A-F) Schematic of the establishment of drug tolerant HCC827 (DTPs) and rederived DTPs cocultured with either RGS5+MYL9+ CAFs or RGS5+MYL9+-d CAFs. (B-E) Flow cytometry is utilized to measure total mitochondrial mass, damaged mitochondria, and MitoSOX levels in HCC827 cells and their cocultured CAFs. (F) Representative electron micrographs display damaged mitochondria in HCC827 cells cocultured with different CAF subsets. (G-J) Schematic representation describes the establishment of drug-tolerant PC9 cells and their rederived counterparts cocultured with RGS5+MYL9+ CAFs or RGS5+MYL9+-d CAFs. (H) Relative cell viability data for PC9 cells. (I-J) Representative electron micrographs illustrate damaged mitochondria in PC9 cells cocultured directly or within a chamber setup with various CAF subsets. The primary CAF subsets utilized in this figure were isolated from patients 04 to 06. Relevant clinical characteristics of these patients are summarized in Supplementary Table 1. Error bars represent mean ± SD, with significance indicated as ns not significant, *P <0.05, **P <0.01, ***P <0.001 according to independent sample t-tests.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer
Figure S7. RGS5+MYL9+ CAFs protect against EGFR-TKI-induced mitochondrial dysfunction in vitro. (A-F) Schematic of the establishment of drug tolerant HCC827 (DTPs) and rederived DTPs cocultured with either RGS5+MYL9+ CAFs or RGS5+MYL9+-d CAFs. (B-E) Flow cytometry is utilized to measure total mitochondrial mass, damaged mitochondria, and MitoSOX levels in HCC827 cells and their cocultured CAFs. (F) Representative electron micrographs display damaged mitochondria in HCC827 cells cocultured with different CAF subsets. (G-J) Schematic representation describes the establishment of drug-tolerant PC9 cells and their rederived counterparts cocultured with RGS5+MYL9+ CAFs or RGS5+MYL9+-d CAFs. (H) Relative cell viability data for PC9 cells. (I-J) Representative electron micrographs illustrate damaged mitochondria in PC9 cells cocultured directly or within a chamber setup with various CAF subsets. The primary CAF subsets utilized in this figure were isolated from patients 04 to 06. Relevant clinical characteristics of these patients are summarized in Supplementary Table 1. Error bars represent mean ± SD, with significance indicated as ns not significant, *P <0.05, **P <0.01, ***P <0.001 according to independent sample t-tests.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer
Figure S8. RGS5+MYL9+ CAFs protect against EGFR-TKI-induced mitochondrial dysfunction in vivo. (A) Flow cytometry analysis assesses total mitochondrial mass, damaged mitochondria levels in tumor cells and CAFs isolated from xenograft mice in Figure 2J. (B) Flow cytometry analysis assesses MitoSOX levels in tumor cells and CAFs isolated from xenograft mice in Figure 2J. Error bars represent mean ± SD, with significance indicated as ns not significant, *P <0.05, **P <0.01, ***P <0.001 according to independent sample t-tests.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer
Figure S8. RGS5+MYL9+ CAFs protect against EGFR-TKI-induced mitochondrial dysfunction in vivo. (A) Flow cytometry analysis assesses total mitochondrial mass, damaged mitochondria levels in tumor cells and CAFs isolated from xenograft mice in Figure 2J. (B) Flow cytometry analysis assesses MitoSOX levels in tumor cells and CAFs isolated from xenograft mice in Figure 2J. Error bars represent mean ± SD, with significance indicated as ns not significant, *P <0.05, **P <0.01, ***P <0.001 according to independent sample t-tests.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer
Figure S2. RGS5+MYL9+ CAFs attenuate EGFR-TKI efficacy in patient-derived organoids. (A) Organoid co-cultures with RGS5+MYL9+ CAFs showed preserved viability (Calcein AM+/PI-) and morphology after 5 μM Osimertinib exposure (days 3-6) compared to RGS5+MYL9+-d CAF controls (B) ATeam biosensor analysis revealed maintained ATP levels (YFP/CFP ratio) in RGS5+MYL9+ CAFs-protected PDOs during treatment, with kinetics showing significant metabolic protection. The primary CAF subsets utilized in this figure were isolated from patients 10 to 12. Relevant clinical characteristics of these patients are summarized in Supplementary Table 1. Error bars are presented as mean ± SD, with statistical significance indicated as ns, not significant, *P <0.05, **P <0.01, ***P <0.001 based on one-way ANOVA followed by Dunnett’s tests.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer
Figure S2. RGS5+MYL9+ CAFs attenuate EGFR-TKI efficacy in patient-derived organoids. (A) Organoid co-cultures with RGS5+MYL9+ CAFs showed preserved viability (Calcein AM+/PI-) and morphology after 5 μM Osimertinib exposure (days 3-6) compared to RGS5+MYL9+-d CAF controls (B) ATeam biosensor analysis revealed maintained ATP levels (YFP/CFP ratio) in RGS5+MYL9+ CAFs-protected PDOs during treatment, with kinetics showing significant metabolic protection. The primary CAF subsets utilized in this figure were isolated from patients 10 to 12. Relevant clinical characteristics of these patients are summarized in Supplementary Table 1. Error bars are presented as mean ± SD, with statistical significance indicated as ns, not significant, *P <0.05, **P <0.01, ***P <0.001 based on one-way ANOVA followed by Dunnett’s tests.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer
Figure S10. Enhanced stromal-tumor proximity in drug-resistant niches. (A-B) Quantitative analysis of CAF-tumor cell distances in (A) treatment-naïve versus (B) Osimertinib-resistant tissues (corresponding to Figure 1J), demonstrating significantly closer association in resistant tumors. (C-D) Spatial analysis of CAF distribution in (C) untreated versus (D) relapsed tumors (from Figure 2Q), revealing preferential peri-tumoral localization of RGS5+MYL9+ CAFs following therapy. Error bars indicate mean ± SD, with statistical significance marked as ns, not significant, *P <0.05, **P <0.01, ***P <0.001 based on one-way ANOVA followed by Dunnett’s tests.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer
Figure S10. Enhanced stromal-tumor proximity in drug-resistant niches. (A-B) Quantitative analysis of CAF-tumor cell distances in (A) treatment-naïve versus (B) Osimertinib-resistant tissues (corresponding to Figure 1J), demonstrating significantly closer association in resistant tumors. (C-D) Spatial analysis of CAF distribution in (C) untreated versus (D) relapsed tumors (from Figure 2Q), revealing preferential peri-tumoral localization of RGS5+MYL9+ CAFs following therapy. Error bars indicate mean ± SD, with statistical significance marked as ns, not significant, *P <0.05, **P <0.01, ***P <0.001 based on one-way ANOVA followed by Dunnett’s tests.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer
Table S1 from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer
Table S1 from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer
Figure S5. RGS5+MYL9+ CAFs mitigate oxidative stress in drug-tolerant persister cells. (A) KEGG pathway analysis of HCC827 cells co-cultured with CAFs reveals significant alterations in oxidative stress-related pathways. (B) KEGG pathway enrichment of between parental HCC827 cells and Osimertinib-induced DTP cells. (C-D) GSEA confirms differential expression of oxidative phosphorylation and reactive oxygen species metabolic pathways in DTP cells compared to parental controls. *P <0.05, **P <0.01, ***P <0.001.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer
Figure S5. RGS5+MYL9+ CAFs mitigate oxidative stress in drug-tolerant persister cells. (A) KEGG pathway analysis of HCC827 cells co-cultured with CAFs reveals significant alterations in oxidative stress-related pathways. (B) KEGG pathway enrichment of between parental HCC827 cells and Osimertinib-induced DTP cells. (C-D) GSEA confirms differential expression of oxidative phosphorylation and reactive oxygen species metabolic pathways in DTP cells compared to parental controls. *P <0.05, **P <0.01, ***P <0.001.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer
Figure S6. RGS5+MYL9+ CAFs facilitate drug-tolerant persister (DTP) formation and tumor regrowth after Osimertinib withdrawal. (A-B) Colony formation assays demonstrate enhanced proliferative recovery of (A) HCC827 and (B) PC9 cells co-cultured with RGS5+MYL9+ CAFs compared to RGS5+MYL9+-d CAFs controls following cyclic Osimertinib treatment (2 μM, 9 days) and withdrawal (n=3). Experiments were performed using paired CAF subsets isolated from three treatment-naïve EGFR-mutant LUAD patients. The primary CAF subsets utilized in this figure were isolated from patients 13 to 15. Relevant clinical characteristics of these patients are summarized in Supplementary Table 1. Data are shown as mean ± SD and were analyzed by a two-tailed unpaired t-test, *P <0.05, **P <0.01, ***P <0.001.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer
Figure S6. RGS5+MYL9+ CAFs facilitate drug-tolerant persister (DTP) formation and tumor regrowth after Osimertinib withdrawal. (A-B) Colony formation assays demonstrate enhanced proliferative recovery of (A) HCC827 and (B) PC9 cells co-cultured with RGS5+MYL9+ CAFs compared to RGS5+MYL9+-d CAFs controls following cyclic Osimertinib treatment (2 μM, 9 days) and withdrawal (n=3). Experiments were performed using paired CAF subsets isolated from three treatment-naïve EGFR-mutant LUAD patients. The primary CAF subsets utilized in this figure were isolated from patients 13 to 15. Relevant clinical characteristics of these patients are summarized in Supplementary Table 1. Data are shown as mean ± SD and were analyzed by a two-tailed unpaired t-test, *P <0.05, **P <0.01, ***P <0.001.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer
Figure S4. RGS5+MYL9+ CAFs foster drug-tolerant persister (DTP) cells through direct cell-cell contact (A-B) Schematic of the establishment of DTP cells (HCC827 and PC9) with or without CAFs in direct contact or separated in a Boyden chamber by a porous membrane. HCC827 and PC9 cells were transduced with ATeam adenovirus before co-culturing with or without different CAF subsets, treated with Osimertinib (2μM) for indicated time. Cell viability was shown by averaged YFP (red) /CFP (Green) emission ratio. (C-D) Relative cell viability of PC9 cells co-cultured (C) (in chamber) (D) with CAF subsets treated with increasing concentration of Osimertinib (0, 0.05, 0.1, 0.5, 1 and 5μM) for 72 hours (n=3). (E) Relative cell viability of HCC827 cells co-cultured (C) (in chamber) (D) with CAF subsets treated with increasing concentration of Osimertinib (0, 0.05, 0.1, 0.5, 1 and 5μM) for 72 hours (n=3). The primary CAF subsets utilized in this figure were isolated from patients 13 to 15. Relevant clinical characteristics of these patients are summarized in Supplementary Table 1. Error bars are presented as mean ± SD, with statistical significance indicated as ns, not significant, *P <0.05, **P <0.01, ***P <0.001 based on one-way ANOVA followed by Dunnett’s tests.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer
Figure S4. RGS5+MYL9+ CAFs foster drug-tolerant persister (DTP) cells through direct cell-cell contact (A-B) Schematic of the establishment of DTP cells (HCC827 and PC9) with or without CAFs in direct contact or separated in a Boyden chamber by a porous membrane. HCC827 and PC9 cells were transduced with ATeam adenovirus before co-culturing with or without different CAF subsets, treated with Osimertinib (2μM) for indicated time. Cell viability was shown by averaged YFP (red) /CFP (Green) emission ratio. (C-D) Relative cell viability of PC9 cells co-cultured (C) (in chamber) (D) with CAF subsets treated with increasing concentration of Osimertinib (0, 0.05, 0.1, 0.5, 1 and 5μM) for 72 hours (n=3). (E) Relative cell viability of HCC827 cells co-cultured (C) (in chamber) (D) with CAF subsets treated with increasing concentration of Osimertinib (0, 0.05, 0.1, 0.5, 1 and 5μM) for 72 hours (n=3). The primary CAF subsets utilized in this figure were isolated from patients 13 to 15. Relevant clinical characteristics of these patients are summarized in Supplementary Table 1. Error bars are presented as mean ± SD, with statistical significance indicated as ns, not significant, *P <0.05, **P <0.01, ***P <0.001 based on one-way ANOVA followed by Dunnett’s tests.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer
Figure S3. RGS5+MYL9+ CAFs Promote EGFR-TKI-Induced DTP. (A-B) ATeam biosensor analysis demonstrates maintained cellular viability (YFP/CFP ratio) in HCC827 (A) and PC9 (B) cells co-cultured with RGS5+MYL9+ CAFs during 2 μM Osimertinib treatment. (C-D) Immunofluorescence staining reveals elevated stemness markers (CD44/CD133) in HCC827 cells protected by RGS5+MYL9+ CAFs under Osimertinib treatment. (E) Western blot shows RGS5+MYL9+ CAF-induced epithelial-mesenchymal transition (EMT) marker expression in Osimertinib treated HCC827 cells. (F) Cell cycle analysis demonstrates RGS5+MYL9+ CAFs-mediated G0/G1 arrest in osimertinib-treated HCC827 and PC9 cells. The primary CAF subsets utilized in this figure were isolated from patients 04 to 06. Relevant clinical characteristics of these patients are summarized in Supplementary Table 1. Data represent mean ± SD (*P<0.05, **P<0.01, ***P<0.001 by one-way ANOVA with Dunnett's test; ns=not significant)
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer
Figure S3. RGS5+MYL9+ CAFs Promote EGFR-TKI-Induced DTP. (A-B) ATeam biosensor analysis demonstrates maintained cellular viability (YFP/CFP ratio) in HCC827 (A) and PC9 (B) cells co-cultured with RGS5+MYL9+ CAFs during 2 μM Osimertinib treatment. (C-D) Immunofluorescence staining reveals elevated stemness markers (CD44/CD133) in HCC827 cells protected by RGS5+MYL9+ CAFs under Osimertinib treatment. (E) Western blot shows RGS5+MYL9+ CAF-induced epithelial-mesenchymal transition (EMT) marker expression in Osimertinib treated HCC827 cells. (F) Cell cycle analysis demonstrates RGS5+MYL9+ CAFs-mediated G0/G1 arrest in osimertinib-treated HCC827 and PC9 cells. The primary CAF subsets utilized in this figure were isolated from patients 04 to 06. Relevant clinical characteristics of these patients are summarized in Supplementary Table 1. Data represent mean ± SD (*P<0.05, **P<0.01, ***P<0.001 by one-way ANOVA with Dunnett's test; ns=not significant)